Skip to content

DBV Technologies DBVT Net Investment in Lease

Net Investment in Lease at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
Alumis Inc. logo
Alumis Inc.ALMS

Other financials

Income statement

See full
Revenue$900.0K+12.5%
Operating income-$47.9M-80.1%
Net income-$47.6M-75.6%
EPS (diluted)-$0.11+57.7%

Balance sheet

See full
Cash & equivalents$229.2M+1,668%
Total debt$6.1M-15.7%
Total equity$207.9M+7,069%
Total assets$266.4M+427%

Cash flow

See full
Operating cash flow-$49.1M-149%
CapEx$400.0K
Free cash flow-$49.5M-151%

Valuation

See full
Market cap$923.31M+269%
Enterprise value$700.21M+188%
P/S159.6×+89.0×

Profitability

See full
Operating margin-2,910.4%-265pp
Net margin-2,895.4%-257pp
FCF margin-2,619.5%+69.9pp

Returns & leverage

See full
Return on equity-158.9%-26.4pp
Debt / equity-2.5×
Current ratio4.8×+4.0×

Where this comes from

Reported directly by DBV Technologies in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: DBV Technologies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about DBV Technologies's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DBV Technologies's net investment in lease?
DBV Technologies (DBVT) reported net investment in lease of $4.2M in Q1 2026.
How has DBV Technologies's net investment in lease changed year-over-year?
DBV Technologies's net investment in lease decreased by 25.2% year-over-year, from $5.61M to $4.2M.
What is the long-term trend for DBV Technologies's net investment in lease?
Over 5 years (2020 to 2025), DBV Technologies's net investment in lease has grown at a -14.6% compound annual growth rate (CAGR), from $10.1M to $4.6M.